Fig 1: Kinetic inhibition of fibronectin 1 (FN1) in HUVECKi2. Relative amount of fibronectin is indicated at each time (h) after treatment. HUVECKi2 was treated with 0.5 µmol/L GO-Y078 (closed rectangle), 1.0 µmol/L GO-Y078 (closed triangle), 1.0 µmol/L sorafenib (closed circle), and 1.0 µmol/L sunitinib (open rectangle). Mock is indicated by open circle. *P < .05, **P < .001
Fig 2: Knockdown effect of fibronectin 1 (FN1) on the growth of HUVECKi2. A, Efficacies of Si-oligos to FN1 mRNA in the attached HUVECKi2. B, Effects on the growth of the attached HUVECKi2 treated with FN1-Si-oligo (open circle), control-Si-oligo (closed rectangle), and without Si-oligo (closed circle). C, Efficacies of Si-oligos to FN1 mRNA in the suspended HUVECKi2. D, Effects of the growth of the suspended HUVECKi2 treated with the FN1-Si-oligo (open circle), control-Si-oligo (closed rectangle), and without Si-oligo (closed circle)
Fig 3: Dose-dependent inhibition of fibronectin 1 (FN1) by GO-Y078. Relative expression values of the Mock (indicated by closed bars) and those of the treated levels with 0.5 µmol/L (shaded bars) and 1.0 µmol/L GO-Y078 (open bars) are indicated. *P < .001, **P < .05. ***no significance
Fig 4: RT-PCR of the candidate transcripts in HUVECKi2 affected by GO-Y078. Relative expression values of the basal levels (closed bars) and those of the treated levels with 0.5 µmol/L GO-Y078 (shaded bars) are indicated. A, fibronectin 1 (FN1); B, other candidates
Supplier Page from Abcam for Human Fibronectin ELISA Kit